Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
about
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersChemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAMAllosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.Drug models of schizophreniaThe antipsychotic potential of muscarinic allosteric modulationAllosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's diseaseDiscovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.Molecular targets for treating cognitive dysfunction in schizophrenia.2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites.M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory lossState-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effectsCholinergic circuits and signaling in the pathophysiology of schizophreniaChanges in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations.Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficitsEnhancement of inhibitory neurotransmission and inhibition of excitatory mechanisms underlie the anticonvulsant effects of Mallotus oppositifolius.Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders.Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats.M1 muscarinic acetylcholine receptor in Alzheimer's diseaseDevelopment of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists.[11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors.Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism.Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia.
P2860
Q24605472-6351FC31-23F3-4B5F-9613-7B0F146852FEQ24631627-9C1931AC-60F5-431F-8464-D07135304B56Q24649568-537F86F4-5E0C-4C3F-BCED-829806A5EFB4Q28084198-E49235F5-E04B-45B6-90A1-CE7F6A882DCDQ28603221-9B68C5DD-9438-4351-9576-94F84D924EDEQ28660933-C8CBF229-951E-4DEF-AA6D-699A2D2C5C0EQ30474039-E9519A56-9029-4F80-9D40-10EB24F617BBQ30491310-A9CBECAF-E772-4A7C-A222-5ABE30EAE6CEQ34243209-782FE7FC-D9A7-4E50-B643-E885E762F06FQ34547610-89869AD0-54EA-42B5-9415-2455AEB01495Q36732752-A88B8D5E-1EE2-4745-B832-DA21433CC8DDQ36756379-B362F82F-DA35-4D66-8B41-F527FE75CBD4Q36799047-6F049C2A-B4A4-437F-8F7D-D6E73FC639F7Q37025888-1032933F-FB7B-4F43-8041-E2D93AD8ECDFQ37058186-46BAC73D-7562-48F6-9F28-D9805F23742FQ37416470-2B0CEF63-B8DD-4ADB-A6D8-79C5BF68E717Q37625841-FE21FF3F-5DD0-4DEC-A80E-10657B37473AQ38192962-C49A6EBF-F85D-48F2-ABEE-C764208008DFQ38665289-DB2A8548-D4E5-4F32-9B54-18D83BBDA58CQ39155961-AC201524-6CAC-4E3E-B658-4B7FCE0B5B68Q39774300-56D40B81-03B5-48E4-87F7-79BB755CB2D1Q41846364-72D38575-BD23-494D-A2C5-7384756A6513Q42093765-8A0EB8BA-051D-4FFA-AA34-16292A0B6B99Q48001582-CDE3559F-AFB9-4578-897F-2E9CFE796571
P2860
Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Xanomeline and the antipsychot ...... or subtype selective agonists.
@ast
Xanomeline and the antipsychot ...... or subtype selective agonists.
@en
Xanomeline and the antipsychot ...... or subtype selective agonists.
@nl
type
label
Xanomeline and the antipsychot ...... or subtype selective agonists.
@ast
Xanomeline and the antipsychot ...... or subtype selective agonists.
@en
Xanomeline and the antipsychot ...... or subtype selective agonists.
@nl
prefLabel
Xanomeline and the antipsychot ...... or subtype selective agonists.
@ast
Xanomeline and the antipsychot ...... or subtype selective agonists.
@en
Xanomeline and the antipsychot ...... or subtype selective agonists.
@nl
P2093
P1476
Xanomeline and the antipsychot ...... tor subtype selective agonists
@en
P2093
Dan Peters
Naheed R Mirza
Robin G Sparks
P304
P356
10.1111/J.1527-3458.2003.TB00247.X
P577
2003-01-01T00:00:00Z